PAVmed Inc.
PAVmed Inc. is a U.S.-based life sciences company organized around a portfolio of medical technologies developed through separate operating subsidiaries. Its business includes diagnostic and cancer-care products, with a focus on devices, tests, and related platforms for unmet clinical needs.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueNon-endoscopic screening and diagnostic tools for Barrett's esophagus and esophageal cancer risk.
Subscription-based cancer care platform services tied to Veris Health.
Development and commercialization of proprietary medical devices and related consumables.
Early-stage product development and incubation of new healthcare technologies.
Customers
PAVmed sells into the healthcare ecosystem rather than directly to consumers, with demand driven by physicians, hospitals, clinical researchers, and healthcare systems. Its diagnostic products are aimed at patients who meet screening-risk criteria, while its platform offerings are used by providers and care organizations that manage cancer-related workflows.
They buy or order EsoGuard and use EsoCheck-based workflows to screen at-risk patients for Barrett's esophagus.
They support clinical deployment, patient collection, and research programs around esophageal screening and cancer care.
They participate in validation studies and grant-funded trials evaluating EsoCheck and EsoGuard.
They use Veris Health platform services for cancer care coordination and related subscription workflows.
Strategy
PAVmed’s strategy is to build and commercialize a portfolio of novel healthcare technologies through a parent-company and subsidiary structure. The company emphasizes product development, clinical validation, and targeted financing at the subsidiary level to support each asset’s path to market.
Clinical adoption depends on evidence, physician acceptance, and workflow integration.
Recurring platform revenue can diversify the business beyond single-product diagnostics.
Capital can be matched to each asset’s development stage and funding needs.
Geography
PAVmed is headquartered in the United States and its reported operating activity is primarily U.S.-based. The company’s products and clinical studies are centered on U.S. physicians, research centers, and healthcare institutions, so domestic regulatory and reimbursement conditions are central to the business.
Risks
PAVmed depends on successful commercialization of a small number of healthcare assets, so adoption, reimbursement, and regulatory outcomes can materially affect results. The business also carries financing and dilution risk because development-stage medical technology companies often rely on equity, convertible securities, and external capital to fund operations.
EsoGuard is tied to laboratory-developed test assumptions and regulatory enforcement discretion.
Exposure: EsoGuard and related diagnostics
Revenue depends on physicians and healthcare systems adopting new screening and care tools.
The company has used ATM equity sales and convertible/preferred structures to fund operations.
Market acceptance of screening products depends on trial outcomes and published validation.
Exposure: NIH-backed EsoCheck/EsoGuard study
Accounting
Judgemental itemsTiming of service delivery and collectability judgments affects when revenue is recorded.
Impact: Can create quarter-to-quarter volatility in reported revenue
Changes in valuation assumptions flow through other income and expense.
Impact: Can materially affect net results without corresponding cash flow
Exchanges and repayments of convertible debt can create gains or losses on extinguishment.
Impact: Can distort period-to-period comparability
ATM sales and preferred conversions increase share count and affect per-share metrics.
Impact: Important for investors modeling ownership dilution
Similar listed companies
Publicly listed companies with a comparable business focus.
Precigen, Inc
PGEN · Pharmaceutical Preparations
RenovoRx, Inc.
RNXT · Surgical & Medical Instruments & Apparatus
Advanced Biomed Inc.
ADVB · Services-Medical Laboratories
Evofem Biosciences, Inc.
EVFM · Pharmaceutical Preparations
Veru Inc
VERU · Pharmaceutical Preparations
P3 Health Partners Inc.
PIII · Services-Health Services
Last updated: 29/04/2026